

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GRANT OF WAIVER IN RELATION TO DELAY IN DESPATCH OF ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

References are made to the announcements of China NT Pharma Group Company Limited (the “**Company**”) dated 31 March 2022, 4 April 2022 and 6 May 2022 (the “**Announcements**”) in relation to the unaudited annual results and further delay in publication of the audited result announcement and annual report of the Company and its subsidiaries (together referred to as the “**Group**”) for the year ended 31 December 2021. Capitalised terms used herein shall have the same meanings as these defined in the Announcements unless otherwise stated herein.

As disclosed in the Announcements, the escalation of the COVID-19 pandemic control quarantine measures and restrictions on travel and logistics in Hong Kong and China have brought practical difficulties to the auditors of the Company in their audit work. The auditing process of the 2021 Annual Results has not yet been fully completed owing to delay in the auditing process and additional time is required for the auditors of the Company to complete the auditing process including but not limited to, obtaining necessary supporting documents and confirmations from customers, suppliers and external parties of the Group.

The Board hereby announces that the Stock Exchange has granted a waiver on 10 May 2022 to the Company from its strict compliance with the requirement of Rules 13.46(2)(a) on the basis that the Company will despatch its annual report for the year ended 31 December 2021 on or before 31 May 2022. The waiver applies to this case only and the Stock Exchange may withdraw or change the terms of the waiver if the Company’s situation changes.

Details of the delay in publication of the audited Annual Results and the despatch of the 2021 Annual Report have been set out in the Announcements and further announcement(s) will be made by the Company as and when necessary if there is any other development in relation thereto.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**China NT Pharma Group Company Limited**  
**NG Tit**  
*Chairman*

Hong Kong, 12 May 2022

*As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Pan Fei and Dr. Zhao Yubiao.*